Canadian health innovators' face 3 primary limitations:
- Small market opportunity in Canada means target the US
- Poor commercialization know-how compared to US innovators
- Closer to the scaling stage compared to other sectors like Green, IT, or even Fintech
C.H.I.E.F.S. – Leveling the playing field for Canadian health innovators.
Know-how: Applying over 28-years of working in, on, or building SMEs, equally split between Canada and the USA.
The Model:
10 FUNCTIONS: Principals, Team, Years, Type of Innovation, Positioning (TAM/SAM/SOM), Early Funding, Currently Seeking, IP, Business Development and Exit Strategy
50 CRITERIA: (proprietary)
Two Components:
C.H.I.E.F.S. Tool™ – screening tool
Virtual matched set – Canadian 11/50 vs US 35/50 (to-date no Canadian innovation has achieved above 21/50 while US companies haven't dipped below 26/50).
Unique pricing model:
Minimal cash outlay/majority of the cost is 'shared risk'(for Outcomes).
"Our ability to share in the risk results from the SME matching the level of funding US innovators typically raise at this point in their development (e.g. $5 million). As such, by directly assisting the company in improving its investibility, Mammoth shares in their success."
"Since we're automatically re-engaged at the six month mark, to determine progress (at no additional cost), therefore we know exactly where their fundraising activities are heading" (Dan Wasserman, Founder & CEO).